Pfizer ready for post-COVID sales

Article Excerpt

Pfizer recently cut its outlook for 2023 due to declining demand for its COVID-19 vaccines and treatments. However, the company is using the huge profits it earned on those products to buy other drugmakers with promising products. We feel these moves, as well as Pfizer’s own highly successful research efforts, set it up for many more years of rising sales and earnings. That will also let the company continue to raise your dividend. PFIZER INC. $31 is a buy. The company (New York symbol PFE; Income Portfolio, Manufacturing & Industry sector; Shares outstanding: 5.65 billion; Market cap: $175.2 billion; Price-to-sales ratio: 2.2; Dividend yield: 5.3%; TSINetwork Rating: Above Average; www.pfizer.com) began operating in 1849 and is now one of the world’s largest makers of prescription drugs. Its top-selling brands include Eliquis (stroke), Ibrance (breast cancer) and Prevnar (pneumonia). In response to the COVID-19 pandemic, Pfizer teamed up with German drugmaker BioNTech (Nasdaq symbol BNTX) to develop a vaccine (called Comirnaty) using messenger ribonucleic acid (mRNA) technology…